Heterocyclic Compounds

Matches 151 - 200 out of 12,063	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2023/232946A1	Organic electroluminescent device comprising a compound of Formula (I) and an organic electronic device comprising the organic electroluminescent device The present invention relates to an organic electroluminescent device comprising a compound of Formula (I), and an organic electronic device comprising the organic electroluminescent device.
WO/2023/232145A1	SMALL MOLECULE OF HOMOCAMPTOTHECINS AND USE THEREOF Disclosed in the present invention are a small molecule of homocamptothecins and the use thereof. Specifically disclosed in the present invention are a small molecule of homocamptothecins as shown in formula (I) or a pharmaceutically acc...
WO/2023/231777A1	COMPOUNDS AS BCL-2 INHIBITORS Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
WO/2023/232966A1	MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF Provided herein are compounds of Formula (I), (I), or pharmaceutically acceptable salt thereof, wherein m, n, p, A1, A2, A3, A4, L, R1, R2, R3, R4, Formula (II), (II), V, X, Y and Z are defined herein. Also provided herein are pharmaceut...
WO/2023/232776A1	HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
WO/2023/226940A1	USE AND PHARMACEUTICAL COMPOSITION OF INDOLO HEPTAMYL OXIME ANALOG The present application relates to the technical field of medicine, and relates to a use and a pharmaceutical composition of an indolo heptamyl oxime analog, and in particular to a use of a compound of formula (I), and a pharmaceutical c...
WO/2023/229430A1	HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF The present invention relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus can be effectively used as a therapeutic agent fo...
WO/2023/225041A1	RIPK1 INHIBITORS AND METHODS OF USE Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related disea...
WO/2023/223057A1	MACROCYCLIC COMPOUNDS AND USES THEREOF The invention relates to selected macrocyclic compounds, and their use in the treatment or prevention of diseases and disorders. In particular, though not exclusively, the invention relates to the use of selected macrocyclic compounds in...
WO/2023/222762A1	N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF The present disclosure relates to proteolysis targeting chimeras (PROTACs) that modulate N6-adenosine-methyltransferase and methods of using the same.
WO/2023/225097A1	PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF Provided are, inter alia, compounds having a structure of Formula (I)-(VL), pharmaceutical compositions including the same, and methods of use. In one aspect, compounds are provided that can inhibit salt-inducible kinases (SIK) and metho...
WO/2023/225302A1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.
WO/2023/224981A1	HSD17B13 INHIBITORS AND USES THEREOF Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
WO/2023/222005A1	AROMATIC HETEROCYCLIC COMPOUND AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF The present invention belongs to the technical field of medicines, and relates to a class of aromatic heterocyclic compounds serving as an LRRK2 inhibitor. The present invention provides a class of compounds with a novel structure, which...
WO/2023/224924A1	SOLID FORMS OF A MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION Processes and methods of preparing Compound I are disclosed. Crystalline forms of Compound I, pharmaceutically acceptable salts, solvates, hydrates, and cocrystals thereof, pharmaceutical compositions comprising the same, methods of trea...
WO/2023/217230A1	KINESIN KIF18A INHIBITOR AND USE THEREOF The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
WO/2023/220129A1	BENZOYPARAZINE PYRAZINES ANE THEIR USES The present disclosure features compounds of Formula I, Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
WO/2023/216871A1	EGFR INHIBITOR AND APPLICATION THEREOF A compound having a structure of formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt thereof, and an application of the compound or salt thereof in inhibiting an EGFR comprising a mutant EGFR, comprising treating canc...
WO/2023/218419A1	PURIFICATION PROCESS OF RIFAMPICIN FROM NITROSAMINES The present invention relates to the control of the quantity of genotoxic impurities, in particular nitrosamines, in rifampicin. In particular, the present invention relates to a process for the preparation of rifampicin substantially fr...
WO/2023/217045A1	FLUOROQUINOXALINONE DERIVATIVE FOR SELECTIVELY INHIBITING PARP1 Disclosed is a series of fluorine-substituted heterocyclic compounds, and specifically, disclosed are a compound represented by formula (XII) and a pharmaceutically acceptable salt thereof.
WO/2023/217201A2	NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF Disclosed in the present invention is a novel pyrimido-heterocyclic compound having WEE1 target inhibitory activity, and specifically discloses a compound having a structure represented by formula (I) or a pharmaceutically acceptable sal...
WO/2023/220541A1	TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Tetrahydropyrido[3,4-d]pyrimidine compounds are provided that are potent HPK1 inhibitors. The compounds are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly hum...
WO/2023/215220A1	MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE The present disclosure provides, in part, compounds of formula (I), or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein; pharmaceutical compositions comprising the compounds; a...
WO/2023/206274A1	ORGANIC ELECTROLUMINESCENT DIODE AND DISPLAY PANEL The present disclosure provides an organic electroluminescent diode and a display panel, belonging to the technical field of display. The organic electroluminescent diode comprises an anode, a luminescent layer, a hole blocking layer, an...
WO/2023/207710A1	ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Provided are an antibody-drug conjugate, a pharmaceutical composition thereof and use thereof. Particularly, provided are an antibody-drug conjugate of formula (I), a drug-linker for preparing the antibody-drug conjugate, and use of the ...
WO/2023/212240A1	COMPOUNDS FOR INHIBITING KIF18A The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to inhibitors of KIF18A and methods o...
WO/2023/210741A1	BENZOTRIAZOLE COMPOUND The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
WO/2023/208124A1	PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF The present application relates to a substituted piperidine carboxamide azaindane derivative, a method for preparing same, and use of a pharmaceutical composition containing the derivative or a deuterated derivative in medicine. Specific...
WO/2023/210623A1	HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
WO/2023/210740A1	BENZOTHIOPHENE COMPOUND The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
WO/2023/208244A1	MACROCYCLIC COMPOUND AND USE THEREOF Disclosed are a novel macrocyclic compound and use thereof, and particularly, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
WO/2023/209368A1	NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein n, R1, R2, R3, R4, R5, A1, A2, A3, A4 and A5 are as defined in the specification, processes...
WO/2023/205701A1	MACROCYCLIC HETEROCYCLES AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, t...
WO/2023/201780A1	METHOD FOR PREPARING QUINOLONE COMPOUND AND INTERMEDIATE THEREOF Provided is a method for preparing a quinolone compound and an intermediate thereof, particularly, a method for preparing quinolone and a pharmaceutical quinolinone intermediate. Specifically, provided are a method for preparing a compou...
WO/2023/202502A1	AZOLE-CONTAINING ORGANIC COMPOUND AND USE THEREOF The present invention relates to an azole-containing organic compound and use thereof. The azole-containing organic compound has a structure represented by structural formula I, , Ar1-Ar3 is one of substituted or unsubstituted C6-C30 ary...
WO/2023/205719A1	KRAS G12D MODULATING COMPOUNDS Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical com...
WO/2023/204308A1	OXAZEPINE DERIVATIVE The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has superior orexin type-2 receptor agonist activity.
WO/2023/200017A1	NOVEL SEVEN-MEMBERED RING-FUSED COMPOUNDS A compound of the formula (I) : wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has a superior Notch signal transduction inhibitory action, and is useful for preventing or treating vari...
WO/2023/198597A1	RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE The present invention relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, ...
WO/2023/196875A1	BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF The present disclosure relates generally to compounds, of Formula I: Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or...
WO/2023/195529A1	URACIL DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME The present invention provides: a compound that exhibits a coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same. The compound is represented by f...
WO/2023/196283A1	EGFR INHIBITORS The present disclosure provides a compound represented by structural formula (A) or (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
WO/2023/195773A1	HETEROARYL DERIVATIVE AND USE THEREOF The present invention relates to a heteroaryl derivative and use thereof. The heteroaryl derivative represented by chemical formula (I) and a pharmaceutical composition including same effectively suppress HER2 activity, and thus are usef...
WO/2023/196959A1	PROCESS FOR MAKING A KRAS G12C INHIBITOR The present disclosure provides the compound of Formula (I): or pharmaceutically acceptable salts thereof, methods and intermediates useful in preparing the compound of Formula (I), pharmaceutical compositions containing the compound of ...
WO/2023/196900A1	SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of...
WO/2023/196629A1	BENZO[H]QUINAZOLINE-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER The invention provides compounds of formula (I); and pharmaceutically acceptable salts thereof; wherein Ra and Rb are both -CH3 or Ra and Rb together form a -CH2-CH2-CH2- or a -CH2-CH2-CH2-CH2- bridging moiety; A is -CH2- or -C(=O)-; T i...
WO/2023/194363A1	METAL-ORGANIC COORDINATION COMPOUND COMPRISING CERIUM(III) A metal-organic coordination compound, wherein the coordination compound comprises at least one Cerium(lll) coordinated by a poly macrocyclic organic ligand having the formula (1-1): • wherein n is an integer of at least 3, • Y at ea...
WO/2023/185704A1	ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE The present invention relates to an isoxazole-heterocyclic derivative, a pharmaceutical composition and use, and specifically provides a compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautome...
WO/2023/192375A1	HSD17B13 INHIBITORS AND USES THEREOF Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, dis...
WO/2023/187051A1	PROCESS FOR THE PRODUCTION OF A TERTIARY AMINE SURFACTANT A process for the production of a surfactant is provided, as well as a surfactant composition. Moreover, specific surfactants and compositions thereof are provided, as well as their use in a wide variety of applications such as all purpo...

Matches 151 - 200 out of 12,063	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >